vs

Side-by-side financial comparison of OCULAR THERAPEUTIX, INC (OCUL) and Americas Gold & Silver Corp (USAS). Click either name above to swap in a different company.

Americas Gold & Silver Corp is the larger business by last-quarter revenue ($19.1M vs $13.3M, roughly 1.4× OCULAR THERAPEUTIX, INC). Americas Gold & Silver Corp runs the higher net margin — -82.3% vs -488.0%, a 405.6% gap on every dollar of revenue. On growth, OCULAR THERAPEUTIX, INC posted the faster year-over-year revenue change (-22.4% vs -28.0%). Americas Gold & Silver Corp produced more free cash flow last quarter ($-41.3M vs $-57.1M).

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

Pan American Silver Corporation is a mining company based in Canada with operations in Latin America. The company has mines and other projects in Mexico, Peru, Bolivia, and Argentina.

OCUL vs USAS — Head-to-Head

Bigger by revenue
USAS
USAS
1.4× larger
USAS
$19.1M
$13.3M
OCUL
Growing faster (revenue YoY)
OCUL
OCUL
+5.6% gap
OCUL
-22.4%
-28.0%
USAS
Higher net margin
USAS
USAS
405.6% more per $
USAS
-82.3%
-488.0%
OCUL
More free cash flow
USAS
USAS
$15.8M more FCF
USAS
$-41.3M
$-57.1M
OCUL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
OCUL
OCUL
USAS
USAS
Revenue
$13.3M
$19.1M
Net Profit
$-64.7M
$-15.7M
Gross Margin
88.0%
34.2%
Operating Margin
-526.5%
Net Margin
-488.0%
-82.3%
Revenue YoY
-22.4%
-28.0%
Net Profit YoY
-33.6%
2.8%
EPS (diluted)
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OCUL
OCUL
USAS
USAS
Q4 25
$13.3M
Q3 25
$14.5M
$19.1M
Q2 25
$13.5M
Q1 25
$10.7M
Q4 24
$17.1M
Q3 24
$15.4M
$26.5M
Q2 24
$16.4M
Q1 24
$14.8M
Net Profit
OCUL
OCUL
USAS
USAS
Q4 25
$-64.7M
Q3 25
$-69.4M
$-15.7M
Q2 25
$-67.8M
Q1 25
$-64.1M
Q4 24
$-48.4M
Q3 24
$-36.5M
$-16.2M
Q2 24
$-43.8M
Q1 24
$-64.8M
Gross Margin
OCUL
OCUL
USAS
USAS
Q4 25
88.0%
Q3 25
87.8%
34.2%
Q2 25
85.6%
Q1 25
88.2%
Q4 24
92.8%
Q3 24
89.9%
23.6%
Q2 24
90.8%
Q1 24
91.0%
Operating Margin
OCUL
OCUL
USAS
USAS
Q4 25
-526.5%
Q3 25
-472.3%
Q2 25
-502.6%
Q1 25
-597.5%
Q4 24
-296.1%
Q3 24
-298.2%
Q2 24
-265.1%
Q1 24
-214.0%
Net Margin
OCUL
OCUL
USAS
USAS
Q4 25
-488.0%
Q3 25
-477.3%
-82.3%
Q2 25
-503.9%
Q1 25
-598.7%
Q4 24
-283.3%
Q3 24
-236.6%
-60.9%
Q2 24
-266.3%
Q1 24
-438.9%
EPS (diluted)
OCUL
OCUL
USAS
USAS
Q4 25
$-0.27
Q3 25
$-0.38
Q2 25
$-0.39
Q1 25
$-0.38
Q4 24
$-0.25
Q3 24
$-0.22
Q2 24
$-0.26
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OCUL
OCUL
USAS
USAS
Cash + ST InvestmentsLiquidity on hand
$737.1M
$39.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$654.3M
$50.2M
Total Assets
$808.1M
$234.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OCUL
OCUL
USAS
USAS
Q4 25
$737.1M
Q3 25
$344.8M
$39.1M
Q2 25
$391.1M
Q1 25
$349.7M
Q4 24
$392.1M
Q3 24
$427.2M
Q2 24
$459.7M
Q1 24
$482.9M
Stockholders' Equity
OCUL
OCUL
USAS
USAS
Q4 25
$654.3M
Q3 25
$258.2M
$50.2M
Q2 25
$305.9M
Q1 25
$265.9M
Q4 24
$315.3M
Q3 24
$352.0M
$53.1M
Q2 24
$377.7M
Q1 24
$408.0M
Total Assets
OCUL
OCUL
USAS
USAS
Q4 25
$808.1M
Q3 25
$410.9M
$234.7M
Q2 25
$451.3M
Q1 25
$405.9M
Q4 24
$457.9M
Q3 24
$490.4M
Q2 24
$517.1M
Q1 24
$538.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OCUL
OCUL
USAS
USAS
Operating Cash FlowLast quarter
$-54.2M
$-12.5M
Free Cash FlowOCF − Capex
$-57.1M
$-41.3M
FCF MarginFCF / Revenue
-430.9%
-216.5%
Capex IntensityCapex / Revenue
21.4%
150.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OCUL
OCUL
USAS
USAS
Q4 25
$-54.2M
Q3 25
$-50.7M
$-12.5M
Q2 25
$-55.2M
Q1 25
$-44.7M
Q4 24
$-39.4M
Q3 24
$-36.6M
$2.4M
Q2 24
$-24.8M
Q1 24
$-33.9M
Free Cash Flow
OCUL
OCUL
USAS
USAS
Q4 25
$-57.1M
Q3 25
$-56.7M
$-41.3M
Q2 25
$-56.5M
Q1 25
$-46.6M
Q4 24
$-39.6M
Q3 24
$-36.6M
$-11.2M
Q2 24
$-25.5M
Q1 24
$-34.1M
FCF Margin
OCUL
OCUL
USAS
USAS
Q4 25
-430.9%
Q3 25
-390.0%
-216.5%
Q2 25
-419.7%
Q1 25
-435.6%
Q4 24
-232.0%
Q3 24
-237.6%
-42.2%
Q2 24
-155.4%
Q1 24
-231.1%
Capex Intensity
OCUL
OCUL
USAS
USAS
Q4 25
21.4%
Q3 25
41.2%
150.8%
Q2 25
9.3%
Q1 25
18.1%
Q4 24
1.2%
Q3 24
0.6%
51.2%
Q2 24
4.5%
Q1 24
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons